Wellness Franchise Opportunities

Wellness blogMar, 16 2016

What made P&G discontinue sales & manufacturing of Vicks Action 500 Extra in India

As the government to banned fixed dose combination drugs, FMCG major Procter and Gamble (P&G) has stopped manufacture and sale of its renowned Vicks Action 500 Extra with immediate effect.

By Pallavi Majha

The Government of India has prohibited the manufacturing, sale and distribution of fixed dose combination drugs, which includes Paracetamol + Phenylephrine + Caffeine with immediate effect, said Pfizer in a BSE filing.

Following the same, FMCG major Procter and Gamble (P&G) has shut manufacturing and sale of its popular brand Vicks Action 500 Extra in India with immediate effect.

Reportedly, the company says, "Our product 'Vicks Action 500 Extra' has the same fixed dose combination and gets covered under notification. We have discontinued the manufacture and sale of all SKUs of 'Vicks Action 500 Extra with immediate effect."

Similarly, drug majors Pfizer and Abbott stopped sale of their popular cough syrups Corex and Phensedyl respectively.

The government banned over 300 fixed dose combinations (FDCs) drugs. The two companies, however, said they are exploring ‘all options’ to counter the impact of ban.

Pfizer said it has stopped the sale of its Corex cough syrup that garnered sales of Rs 176 crore in the nine-month period ended December 31, and said the government's move will have an adverse impact on it.

"The company is exploring all available options at its disposal... The prohibition is likely to have an adverse impact on the revenue and profitability of the company," Pfizer had said in a BSE filing.

In view of the government ban on manufacture and sale of Corex, the "company has discontinued the manufacture and sale of its drug 'Corex' with immediate effect," Pfizer said adding that Corex has a well established efficacy and safety profile in India for more than 30 years.

Abbott also stopped sale of its Phensedyl cough syrup. When contacted a company spokesperson said: "Abbott is complying with all legal requirements related to the government notification." The company termed the Health Ministry's decision to ban "certain fixed dose combinations drugs that have been already approved" as a "unilateral approach".

"Abbott has reviewed the DCGI notification and we are concerned about the unilateral approach in prohibiting the manufacture, sale and distribution of certain fixed dose combinations that have already been approved for use by DCGI. “We are evaluating the notification and exploring all available options," the spokesperson said.

Some of these formulations have been the treatment of choice in specific medical conditions, Abbott said. "We are concerned that patients may not have access to some medicines which have been approved by DCGI and safely and effectively used in India for years," Abbott spokesperson said. In a gazette notification on March 10, the government had, among others, banned manufacture, sale and distribution of fixed does combination of chlopheniramine maleate plus codiene syrup which is used in the cough syrups.

Related: 6 lucrative ways to entice your regular customers

Click Here to add Comment
Please add your Comment
Rating
Sell Business 2017
Sell Franchise 2017

Newsletter Signup

Submit your email address to receive the latest updates on news & host of opportunities from Wellness India.

Video

Magazines & Books

Read the latest franchising magazines and books to get comprehensive and up-to-date information on leading franchise systems, trends and more.

Recommended For You

Newsletter Signup
Submit your email address to receive the latest updates on news & host of opportunities.
Well Ness India

Copyright © 2009 - 2017 Franchise India Holdings Ltd.

The information contained herein is of generic nature only, and Franchise India is not, by means of this website or any part thereof, rendering professional advice or services. Before making any decision or taking any action that might affect your finances or business, you should consult a qualified professional advisor. Your use of this website or any of its pages or links given, is at your own risk and you assume full responsibility and risk of loss resulting from your usage. With respect to use of the website, kindly visit www.franchiseindia.com/terms.